Galectin has prelim data from Phase 1b trial of Keytruda combo

Galectin Therapeutics announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b clinical trial of GR-MD-02 used in combination with Keytruda in patients with metastatic melanoma for which Keytruda is indicated or those patients whose melanoma progressed during or recently after Keytruda monotherapy. The Providence Cancer Institute translational medicine team is conducting this phase 1b clinical trial, initiated under direction of principal investigator Brendan D. Curti. The objectives of this study were to determine a safe dose of GR-MD-02 used in combination with Keytruda and to measure the response rate to combined therapy. When aggregated with the cohorts previously reported, the data shows a 50% objective response rate in advanced melanoma with GR-MD-02 in combination with Keytruda, and a significant decrease in the frequency of suppressive myeloid-derived suppressor cells, or MDSC, following treatment in the responding patients was observed. The published data on Keytruda alone have shown an objective response rate of 33% in this patient population. Fourteen advanced melanoma patients across three dose cohorts now have objective response rate, or ORR and disease control rate, or DCR, data. Six patients in cohort 3 have now been added to the three patients in cohort 2 and the five patients in cohort 1. Cohorts 1 and 3 each had two patients with an objective response. All three patients in cohort 2 had an objective response.
https://thefly.com/landingPageNews.php?id=2793063